Vical Inc. (Nasdaq: VICL) said Wednesday that it licensed its Vaxfectin technology, which is designed to make vaccines more effective, to a company that intends to use it in malaria vaccines.
Vical said privately held Cyvax is licensing Vaxfectin. The companies did not disclose financial terms of the agreement.
Vical also announced a licensing agreement with drugmaker Bristol-Myers Squibb Co. (NYSE: BMY) in September.
Shares of Vical declined a penny to $3 in morning trading.
All contents herein copyright San Diego Source ® 1994-2018